Elsevier

Gynecologic Oncology

Volume 66, Issue 2, August 1997, Pages 262-267
Gynecologic Oncology

Regular Article
Hydroxyurea, 5-Fluorouracil Infusion, and Cisplatin Adjunct to Radiation Therapy in Cervical Carcinoma: A Phase I–II Trial of the Gynecologic Oncology Group

https://doi.org/10.1006/gyno.1997.4761Get rights and content

Abstract

Background.In a previous study, the Gynecologic Oncology Group (GOG) compared hydroxyurea (HDXR) and the combination of cisplatin (C) and 5-fluorouracil (5-FU) infusion as potentiators of radiation therapy. This study was undertaken to determine whether these two regimens could be combined, concurrent with pelvic radiation therapy in patients with locally advanced cervical cancer.

Methods.The GOG entered 75 eligible and evaluable patients on a Phase I–II evaluation of HDXR, C, and 5-FU as adjuncts to radiation therapy for locally advanced carcinoma of the cervix. All patients had histologically verified primary disease and confirmed negative para-aortic lymph nodes. Eligibility was limited to clinical stage IIB through IVA. HDXR was given orally, twice weekly at a dose of 2.5 g/m2; C on Days 1 and 29 at 50 mg/m2; and 5-FU by 96-hr infusion on Days 2–5 and 30–33 at a starting dose of 800 mg/m2.

Results.Forty-eight (64%) patients had stage IIB disease, 25 (33%) had stage IIIB, and 2 had stage IVA tumors. Primary tumors 4 cm or less in size were present in 15 patients, between 4 and 6 cm were in 27 patients, and larger than 6 cm were observed in 33 patients. Grade 3/4 acute toxicity was experienced by 41 (54.7%) patients. These acute toxicities caused delays in prescribed radiation therapy of more than 1 week in 14 (18.9%) and low doses of drug in 16 (21.3%), and only 26 (34.7%) patients had the scheduled dose escalation of 5-FU on their second course. Clinical response was excellent with complete and partial response rate of 93.3%. Median time to progression has not been reached.

Conclusion.Although this dose and schedule could be successfully administered, the delays in therapy should be avoided by a lower starting dose of hydroxyurea. Stomatitis was not a dose-limiting toxicity. These results have formed the basis of a phase III trial comparing this regimen to two other chemoradiation regimens.

References (26)

  • MM Hreschyshyn et al.

    Hydroxyurea or placebo combined with radiation to treat stages III B and IV cervical cancer confined to the pelvis

    Int J Radiat Oncol Biol Phys

    (1979)
  • FB Stehman et al.

    Hydroxyurea versus misonidazole with radiation in cervical carcinoma: long term follow-up of a Gynecologic Oncology Group trial

    J Clin Oncol

    (1993)
  • Cited by (38)

    • Is age a prognostic biomarker for survival among women with locally advanced cervical cancer treated with chemoradiation? An NRG Oncology/Gynecologic Oncology Group ancillary data analysis

      2016, Gynecologic Oncology
      Citation Excerpt :

      Patients took hydroxyurea orally twice weekly during external radiation. Chemotherapy was held for white blood cell (WBC) < 3000/μl or platelets < 100,000/μl [11]. All 75 patients enrolled in GOG 113 were included in this ancillary analysis.

    • Update on the treatment of advanced cervical cancer

      2002, Critical Reviews in Oncology/Hematology
    • Chemoradiotherapy for cervical cancer

      2002, European Journal of Cancer
    View all citing articles on Scopus

    Address reprint requests to: GOG Administrative Office, Suite 1945, 1234 Market Street, Philadelphia, PA 19107.

    View full text